IGM Biosciences ( (IGMS) ) just unveiled an update.
IGM Biosciences, Inc. is refocusing its efforts from oncology to the development of T cell engagers for autoimmune diseases, extending its cash runway into 2027. The company is reducing its workforce and minimizing investment in its oncology pipeline, including aplitabart. Concurrently, Mary Beth Harler, M.D., with extensive experience in autoimmunity, has been appointed as CEO. IGM’s lead autoimmune candidate, imvotamab, is progressing in clinical development for rheumatoid arthritis and systemic lupus erythematosus, with initial data expected soon.
See more data about IGMS stock on TipRanks’ Stock Analysis page.
